Prevalence of certain unhealthy behaviors decreased, while self-rated health improved, regardless of cancer history
Blood Biomarker Linked to Incident VTE in COVID-19 Patients
Higher levels of soluble urokinase plasminogen activator receptor linked to incident venous thromboembolism independently of D-dimer
Drop Seen in Transplantation in 2020 With COVID-19 Pandemic
Decrease noted in transplants and in waitlist registrations for transplants compared with those expected
First Lady Jill Biden Leaves Isolation After Testing Negative for COVID-19 Twice
Jill Biden first tested positive for COVID-19 last Tuesday
Pfizer Asks FDA to Approve Omicron-Specific Booster Shot
Animal studies show that the new mRNA vaccine produces an immune response against both BA.4 and BA.5 subvariants
First HIV, Monkeypox, SARS-CoV-2 Coinfection Confirmed
A new Letter presented the clinical features and diagnostic procedure of the first documented case of co-infection with monkeypox virus, SARS-CoV-2, and HIV-1 in an Italian 36-year-old male.
Published on August 19, 2022, by the peer-review Journal of Infection, this case highlights how monkeypox disease and COVID-19 symptoms may overlap and corroborates how in case of co-infection, anamnestic collection and sexual habits are crucial to perform the correct diagnosis.
The WHO Issues Strong Recommendations for Ebola Monoclonal Antibodies
The World Health Organization (WHO) published its first guideline for Ebola virus disease (EVD) therapeutics following a systematic review and meta-analysis of randomized clinical trials, with strong recommendations for using two monoclonal antibodies, Ebanga and Inmazeb.
The WHO stated on August 19, 2022, that EVD is a severe and too often fatal illness caused by the Ebola virus and called on the global community to increase access to these lifesaving monoclonal antibodies (mAbs) treatments.
This Mosquito-borne Viral Disease May Soon Be Prevented with an Innovative Vaccine
After many years of focused research, an innovative vaccine candidate may become available in 2023 to combat the chikungunya virus, which has spread to over 120 countries.
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV) transmitted to humans by a bite from Aedes mosquitoes.
The U.S. CDC says a CHIKV infection leads to symptomatic disease in 72-92% of humans after a few days.
While mortality is low, CHIKV morbidity is high.
This disease can impact over 30% of the population in areas where CHIKV is circulating.
Chronic Neuropsychiatric Symptoms Confirmed After COVID-19
Self-reported neurologic symptoms seem not to correlate with associated quantitative dysfunction
Metformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
No difference in the primary end point seen with any of the three medications versus placebo among adults with overweight or obesity